Kilitch Drugs (India) Limited Share Price and Company Fundamentals
Last traded: Yesterday at 9:59 AM
Kilitch Drugs (India) Limited engages in the development and operation of the pharmaceutical business in India and internationally. The company offers various parenteral, nasal, and topical products, such as liquid ampoules, vials, dry powder injectables, and metered nasal drops for gastroenterology, non-steroidal anti-inflammatory, anticonvulsant/antiepileptic, anti-malarial, aminoglycoside, antibacterial, anti-hypertensive, anti-infective, diagnostic, sympathomimetic, local anesthetic, neurotonic, uterine stimulant, external preparation, anticoagulant, narcotic, oncology, ophthalmic, antifungal, corticosteroid, anticoagulant, and other applications, as well as vaccines, veterinary products, iron supplements for anemia, Klavmox, and Onecef. It also provides oral formulations, including tablets, capsules, dry syrup, and oral powder for antibiotic, anti-diabetic, cardiovascular, and other areas; effervescent tablets and powders, such as Roipar, Duregra, and Roivit; and nutritional products, including Celtine. In addition, the company offers cosmetics, which include oil, lotion, liquid to cream, paste in skin, and personal and hair care products; herbal products for use in sore throat and prostate problems, as well as a supplement for diabetes, obesity, libido, and other conditions; ortho rehabilitation and implants; and medical devices comprising C-Seal, a skin adhesive to hold closely approximated skin edges without marks of sutures and incisions. Further, it provides PH-7 which reduces acid content of the stomach; SRO kit for treating childhood diarrhea; 9-VIT for use in surgery, extensive burns, fractures, and other trauma; and HPURE for sore throat and cough. The company exports its products. Kilitch Drugs (India) Limited was founded in 1978 and is headquartered in Mumbai, India.
Key Metrics
PE ratio
20.41
PB ratio
1.99
Dividend yield
-
Beta
-0.24
Market cap
₹5.61B
Enterprise value
₹5.55B
Company profile
| Industry / Sector | Drug Manufacturers - Specialty & Generic / Healthcare |
|---|---|
| Full time employees | 187 |
| Website | https://kilitch.com |
| Mailing address | 37/39, Ujagar Industrial Estate Waman Tukaram Patil Marg Deonar Mumbai 400088 India |
| Phone / Fax | 91 22 6121 4100 / 91 22 6703 1658 |
Dividends
Dividend yield
-
Dividend amount
₹-
Payout ratio
0.00%
5Y Avg. yield
-%
Kilitch Drugs (India) Limited paid ₹- dividend and the ex-dividend date was 20 Sep 2019.The dividend payout ratio is 0.00%. The dividend payout ratio is defined as the amout of dividend paid divided by the earnings of the company.KILITCH dividend payout ratio is less than 70. This is ideal as it gives company room to grow the dividends and also the excess earnings can be invested in company for growth.
Company Executives
As of Mar 2026, following are the company executives and directors listed on Kilitch Drugs (India) Limited.
| Name | Title | Age | Total Pay |
|---|---|---|---|
| Mr. Mukund Prataprai Mehta B.Com., LL.B. | Executive Chairman & MD | 72 | |
| Ms. Mira Bhavin Mehta | MD & Director | 47 | |
| Mr. Bhavin Mukund Mehta B.Pharm. | Whole-time Director | 49 | |
| Mr. Sunil Sureshji Jain | Chief Financial Officer | 42 | |
| Tajouddin Ansari | VP-Marketing & Operation | ||
| Rajesh Khatri | General Manager - Administration | 50 | |
| Ms. Pushpa Nyoupane | Company Secretary & Compliance Officer |
Profitability and management effectiveness
Profit margin
12.76%
Operating margin
9.69%
Return on assets
-
Return on equity
-
Profitability ratios are a class of financial metrics that are used to assess a business's ability to generate earnings relative to its revenue, operating costs, balance sheet assets, and shareholders' equity over time, using data from a specific point in time.
The return on equity signifies how well the management is running the company in terms of capital management. The ideal return on equity is greater than 10%. The return on equity is calculated as net income divided by total share holders equity.
Valuation and Trading Info
The market capitalization of Kilitch Drugs (India) Limited is 5.61B and its enterprise value is 5.55B. The enterprise value to revenue ratio of KILITCH is 2.68. The enterprise value to EBITDA ratio of KILITCH is 19.25.
Kilitch Drugs (India) Limited (NSE:KILITCH) Frequently Asked Questions
1. What is Kilitch Drugs (India) Limited's Stock Symbol?
Kilitch Drugs (India) Limited trades on NSE under the ticker symbol "KILITCH".
2. What is Kilitch Drugs (India) Limited's stock price today?
One share of KILITCH stock can currently be purchased for approximately ₹320.1.
3. How can I contact Kilitch Drugs (India) Limited?
Kilitch Drugs (India) Limited's mailing address is 37/39, Ujagar Industrial Estate Waman Tukaram Patil Marg Deonar Mumbai 400088 India. The company can be reached via phone at 91 22 6121 4100.
4. What is Kilitch Drugs (India) Limited's official website?
The official website of Kilitch Drugs (India) Limited is https://kilitch.com.